BioLargo, Inc. Files 8-K Report
Ticker: BLGO · Form: 8-K · Filed: Nov 15, 2024 · CIK: 880242
Sentiment: neutral
Topics: 8-K, filing, disclosure
TL;DR
BioLargo filed an 8-K, mostly boilerplate but check for exhibit details.
AI Summary
On November 14, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that BioLargo, Inc. is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's financial status or regulatory compliance.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- BioLargo, Inc. (company) — Registrant
- November 14, 2024 (date) — Date of earliest event reported
- 14921 Chestnut St. (address) — Principal executive offices
- Westminster, California (location) — Principal executive offices location
- 92683 (zip_code) — Principal executive offices zip code
FAQ
What is the primary purpose of this 8-K filing for BioLargo, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits, as indicated by the filing information.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is November 14, 2024.
Where are BioLargo, Inc.'s principal executive offices located?
BioLargo, Inc.'s principal executive offices are located at 14921 Chestnut St., Westminster, California, 92683.
What is BioLargo, Inc.'s state of incorporation?
BioLargo, Inc.'s state of incorporation is Delaware.
What is the SEC file number for BioLargo, Inc.?
The SEC file number for BioLargo, Inc. is 000-19709.
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-11-15 06:01:22
Filing Documents
- blgo20241114_8k.htm (8-K) — 29KB
- ex_748380.htm (EX-99.1) — 19KB
- ex_748568.htm (EX-99.2) — 11KB
- a01.jpg (GRAPHIC) — 53KB
- a02.jpg (GRAPHIC) — 77KB
- a03.jpg (GRAPHIC) — 52KB
- a04.jpg (GRAPHIC) — 51KB
- a05.jpg (GRAPHIC) — 62KB
- a06.jpg (GRAPHIC) — 69KB
- a07.jpg (GRAPHIC) — 47KB
- a08.jpg (GRAPHIC) — 56KB
- a09.jpg (GRAPHIC) — 38KB
- a10.jpg (GRAPHIC) — 74KB
- a11.jpg (GRAPHIC) — 61KB
- a12.jpg (GRAPHIC) — 63KB
- a13.jpg (GRAPHIC) — 64KB
- a14.jpg (GRAPHIC) — 59KB
- a15.jpg (GRAPHIC) — 55KB
- a16.jpg (GRAPHIC) — 67KB
- a17.jpg (GRAPHIC) — 58KB
- a18.jpg (GRAPHIC) — 57KB
- a19.jpg (GRAPHIC) — 46KB
- a20.jpg (GRAPHIC) — 71KB
- a21.jpg (GRAPHIC) — 67KB
- a22.jpg (GRAPHIC) — 57KB
- a23.jpg (GRAPHIC) — 90KB
- a24.jpg (GRAPHIC) — 59KB
- a25.jpg (GRAPHIC) — 75KB
- a26.jpg (GRAPHIC) — 68KB
- a27.jpg (GRAPHIC) — 66KB
- a28.jpg (GRAPHIC) — 52KB
- a29.jpg (GRAPHIC) — 61KB
- a30.jpg (GRAPHIC) — 59KB
- a31.jpg (GRAPHIC) — 68KB
- chart.jpg (GRAPHIC) — 8KB
- 0001437749-24-035426.txt ( ) — 2821KB
- blgo-20241114.xsd (EX-101.SCH) — 3KB
- blgo-20241114_def.xml (EX-101.DEF) — 11KB
- blgo-20241114_lab.xml (EX-101.LAB) — 14KB
- blgo-20241114_pre.xml (EX-101.PRE) — 11KB
- blgo20241114_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. BioLargo, Inc., presented the slides attached as Exhibit 99.1 , which are incorporated herein by reference, on November 14, 2024, at 1:30 PM Pacific Time, at a webcast investor conference. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01, in the slide presentation attached as Exhibit 99.1 to this Current Report, and the press release attached as Exhibit 99.2 to this Current Report, shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading "Safe Harbor Act" in the exhibits attached hereto.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Slide deck presentation 99.2 Press release dated November 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 14, 2024 BIOLARGO, INC. By: /s/ Dennis P. Calvert Dennis P. Calvert President and Chief Executive Officer